Recommendations on prevention of infections during chimeric antigen receptor T ‐cell and bispecific antibody therapy in multiple myeloma
British Journal of Haematology · 2023-12 · 203 (5) · 736-746
DOI: 10.1111/bjh.18909 ↗Kurz gefasst
Fallbericht in der Zeitschrift British Journal of Haematology, online erschienen am 07.06.2023. Verfasst von Meera Mohan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Multiple Myeloma, Antibodies, Bispecific, Leukopenia. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T‐cell exhaustion, cytokine‐release syndrome and immune‐effector cell‐associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T‐cell and bispecific antibody therapies in MM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York City, New York, USA.
- Division of Hematology and Medical Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
- Sarah Cannon Research Institute, Nashville, Tennessee, USA.
ORCID-Profile: Meera Mohan, Muhamed Baljevic, Anita D'Souza, Luciano J Costa
Förderung
- NCI NIH HHS
Zitieren
APA
Mohan, M., Chakraborty, R., Bal, S., Nellore, A., Baljevic, M., D'Souza, A., Pappas, P. G., Berdeja, J. G., Callander, N., & Costa, L. J. (2023). Recommendations on prevention of infections during chimeric antigen receptor T ‐cell and bispecific antibody therapy in multiple myeloma. British Journal of Haematology, 203(5), 736-746. https://doi.org/10.1111/bjh.18909
Vancouver
Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, D'Souza A, et al. Recommendations on prevention of infections during chimeric antigen receptor T ‐cell and bispecific antibody therapy in multiple myeloma. British Journal of Haematology. 2023;203(5):736-746. doi:10.1111/bjh.18909
BibTeX
@article{Mohan2023,
author = {Mohan, Meera and Chakraborty, Rajshekhar and Bal, Susan and Nellore, Anoma and Baljevic, Muhamed and D'Souza, Anita and Pappas, Peter G and Berdeja, Jesus G and Callander, Natalie and Costa, Luciano J},
title = {Recommendations on prevention of infections during chimeric antigen receptor T ‐cell and bispecific antibody therapy in multiple myeloma},
journal = {British Journal of Haematology},
year = {2023},
volume = {203},
number = {5},
pages = {736--746},
doi = {10.1111/bjh.18909}
}
EUVIMED